【正文】 nd PPARa activators, similar effects Similar effector, PPARa? Statins induce PPARa activity Human apo AI mRNA is induced by statins in a dosedependent manner Statins act on apo AI mRNA expression at the transcriptional level Inhibition by actinomycin D Statin effect on apo AI synthesis is related to its mode of action Inhibition by mevalonate Statins and PPARa activators increase human apo AI gene expression Simvastatic acid reduces induced LPS MMP9 secretion Parietal vascular effects of statins (1) Endothelial cells Parietal vascular effects of statins (2) Monocytes, macrophages PPARa activators act on the main factors involved in the onset of atherosclerosis VAHIT VAHIT cont DAIS DAIS cont HHS HHS cont 4S 4S cont CARE CARE cont WOSCOPS WOSCOPS cont LIPID LIPID cont AFCAPS/TexCAPS AFCAPS/TexCAPS cont AVERT AVERT cont HPS HPS cont NCEP guidelines NCEP guidelines cont NCEP guidelines cont NCEP guidelines cont AHA/ACC guidelines ADA guidelines ADA guidelines cont Lipid management for primary prevention of CHD in adults – ILIB remendations Lipid management for secondary prevention of CHD in adults – ILIB remendations Lipid management for secondary prevention of CHD in adults with diabetes mellitus – ILIB remendations Abbreviations list ? AS Atherosclerosis ? BL Baseline ? BMI Body Mass Index ? BP Blood Pressure ? CABG Coronary Artery Bypass Graft ? CAD Coronary Artery Disease ? CARE Cholesterol and Recurrent Events ? CE Cholesterol Ester ? CERP Cholesterol Efflux Regulatory Protein ? CETP Cholesterol Ester Transfer Protein ? CHD Coronary Heart Disease ? CHF Congestive Heart Failure ? Chol Cholesterol ? COX2 Cyclooxygenase2 ? CRP C Reactive Protein ? CV Cardiovascular ? CVD Cardiovascular Disease ? DM Diabetes Mellitus ? ECTIM Study Etude CasTemoins de I237。 30–42. ? Figures 42. Fruchart JC. Physiology of lipids and lipoproteins. Prev Cardiol 1999。 2324–2335. ? Figure 48. Luc G, Fievet C, Arveiler D Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P. Apolipoproteins CIII and E in apoB and nonapoBcontaining lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur ‘Infarctus du Myocarde’. J Lipid Res 1996。 2453–2458. ? Figure 58. Knowler WC, Pettitt DJ and Saad MF, et al. Obesity in the Primas Indians. Its magnitude and relationship with diabetes. Am J Clin Nutr 1991。 353–354. ? Figure 75, 76, 77 and 78. Pennancchio LA, Oliver M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and Mice revealed by parative sequencing. Science 2022。24N–29N. ? Figure 87, 88, 89, 92, 94 and 94. Staels B, Keonig W, Habib A, Merval R, Lebret M, Pineda Torra I,Delerive P, Fadel A, Chiti G, Fruchart JC, Najib J, Maclouf J, Tedgui A . Activation of human aortic smoothmuscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998。 394–402. ? Figures 98. Neve BP, Corseaux D, Chiti G Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARa agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2022。 207–212. ? Figures 99. Gervois P, VuDac R,